<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507166</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C005</org_study_id>
    <nct_id>NCT03507166</nct_id>
  </id_info>
  <brief_title>A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer</brief_title>
  <official_title>A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with
      local advanced or metastatic HER2 positive endothelial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Drug: RC48-ADC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as Assessed by investigator</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Tumor response was assessed by investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS was defined as the time from the first study treatment to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <description>2 mg/kg IV every 2 weeks</description>
    <arm_group_label>RC48-ADC</arm_group_label>
    <other_name>Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary agreement to provide written informed consent.

          -  Male or female, Age ≥ 18 years and ＜ 80 years.

          -  Predicted survival ≥ 12 weeks.

          -  Have histologically or cytologically-confirmed diagnosis of inoperable, locally
             advanced or metastatic urothelial cancer of the bladder, renal pelvis, ureter.

          -  Have had progression or intolerance following receipt of at least one systemic
             chemotherapy for advanced or metastatic disease.

          -  Measurable disease according to RECIST 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          -  Adequate organ function, evidenced by the following laboratory results:

        Cardiac ejection fraction ≥ 50 %. Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥ 1.5×109
        /L Platelets ≥ 100×109 /L; Total bilirubin ≤ 1.5× ULN; AST, ALT, and ALP ≤ 2.5×ULN and ≤ 5
        x ULN with hepatic metastasis; Serum creatinine ≤1.5×ULN.

          -  All female subjects will be considered to be of child-bearing potential unless they
             are postmenopausal, or have been sterilized surgically.Female subjects of
             child-bearing potential must agree to use two forms of highly effective contraception.
             Male subjects and their female partner who are of child-bearing potential must agree
             to use two forms of highly effective contraception.

          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions
             specified in this protocol.

        Exclusion Criteria:

          -  Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE
             Conjugate For Injection.

          -  History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to
             trial treatment.

          -  History of receiving Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE
             Conjugate For Injection.

          -  History of major surgery within 4 weeks of planned start of trial treatment.

          -  Has received a live virus vaccine within 4 weeks of planned start of trial treatment.

          -  Currently known active infection with HIV or tuberculosis.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  History of other malignancy within the previous 5 years, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with
             a similar curative outcome as those mentioned above.

          -  known central nervous system metastases.

          -  Pregnancy or lactation.

          -  Assessed by the investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Fang</last_name>
    <phone>+8610-58075763</phone>
    <email>jianminfang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>N/A = Not Applicable</state>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>N/A = Not Applicable</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aiping zhou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RC48-ADC</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

